Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan writes that US biotech companies are holding ...
July 11, 2026 06:00 AM EDT
Weekly
Deals, deals, deals; Biohaven takes on Eli Lilly; and more
Max Gelman
Nicole DeFeudis
Welcome back to Endpoints Weekly! This week, we opened nominations for our eighth annual Women in Biopharma report. We’re looking…
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s…
Welcome back to another edition of Endpoints Weekly. My usual colleague Nicole DeFeudis is out this week, so I’ve assembled the…
RIP Sangamo, onshoring with drug manufacturing, and more biotech news from The Readout
Eli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout
A $10B deal, China trial scrutiny and highlights from ADA 2026
Roche ends Huntington's gene-silencing programs
Four major biotech updates to catch up on
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
Prime wins Beam arbitration, clearing path to clinic
Akero team, backed by Fairmount, launches new immunology company
